Literature DB >> 8422455

Hematopoietic growth factors and their receptors in acute leukemia.

B Löwenberg1, I P Touw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8422455

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

1.  Marked increase of normal blast morphologically mimicking leukemic clone in acute lymphoblastic leukemia patient following G-CSF therapy.

Authors:  Osamu Imataki; Hiroaki Ohnishi; Genji Yamaoka; Takeshi Arai; Akira Kitanaka; Yoshitsugu Kubota; Toshihiko Ishida; Terukazu Tanaka
Journal:  Int J Hematol       Date:  2008-10-07       Impact factor: 2.490

2.  Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

Authors:  Steven M Kornblau; David McCue; Neera Singh; Wenjing Chen; Zeev Estrov; Kevin R Coombes
Journal:  Blood       Date:  2010-08-02       Impact factor: 22.113

3.  Cytokine production by a megakaryocytic cell line.

Authors:  B Sandrock; K M Hudson; D E Williams; M A Lieberman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

Review 4.  Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia.

Authors:  S Bolam; T Hamblin
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

Review 5.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

6.  Value of colony forming unit-granulocyte macrophage assay in predicting relapse in acute myeloid leukaemia.

Authors:  M C del Cañizo; A Mota; A Orfao; J Galende; M D Caballero; M A Garcia Marcos; J F San Miguel
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

7.  Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT.

Authors:  T Czerw; M Labopin; N-C Gorin; S Giebel; D Blaise; P-Y Dumas; R Foa; M Attal; N Schaap; M Michallet; C Bonmati; H Veelken; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

Review 8.  Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making?

Authors:  Charles L Bennett; Glen T Schumock
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Authors:  May Kung Sutherland; Changpu Yu; Timothy S Lewis; Jamie B Miyamoto; Carol A Morris-Tilden; Mechthild Jonas; Jennifer Sutherland; Albina Nesterova; Hans-Peter Gerber; Eric L Sievers; Iqbal S Grewal; Che-Leung Law
Journal:  MAbs       Date:  2009-09-15       Impact factor: 5.857

Review 10.  The implications of cancer stem cells for cancer therapy.

Authors:  Wenjing Jiang; Jianhua Peng; Yue Zhang; William C S Cho; Kunlin Jin
Journal:  Int J Mol Sci       Date:  2012-12-05       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.